Dyspnoea in COPD patients heralds worse outcomes

By Joanna Lyford, Senior medwireNews Reporter

Breathlessness is a common finding in patients with chronic obstructive pulmonary disease (COPD) and signals an increased risk of exacerbations, study findings indicate.

The research included 49,438 patients with COPD whose details were included in a UK primary care research database, of whom 82% had been assessed using the Medical Research Council (MRC) dyspnoea scale.

The patients’ mean age was 69.2 years, 46% were women and 33% were current smokers.

In all, 38% had an MRC score of 2, indicating mild dyspnoea, while 46% had a score of 3 or greater, indicating moderate-to-severe dyspnoea, report lead author Hana Müllerová (GlaxoSmithKline R&D, Uxbridge, UK) and team writing in PLoS One.

Compared with patients with less severe disease, those with moderate-to-severe COPD were significantly older (70.7 vs 67.8 years on average), were more often female (48 vs 44%), had worse lung function (44 vs 23% with an FEV1 <50% predicted), had more comorbidities, and were more intensively treated with COPD medications.

They had also been treated more frequently for exacerbations in the previous year (1.0 versus 0.6 events per person per year).

A subgroup of 38,256 patients had 12-month follow-up data available. Analysis of this cohort revealed a positive correlation between dyspnoea grade at baseline and subsequent risk of COPD exacerbations.

For instance, 33% of patients without dyspnoea (MRC grade 1) suffered a moderate-to-severe exacerbation versus 67% of those with MRC grade 5. For severe COPD exacerbations, the figures were 7% versus 24%.

Müllerová and colleagues remark that while breathlessness increased with increasing airflow limitation, one third of patients with only mild airflow obstruction nevertheless had moderate-to-severe dyspnoea.

“In conclusion, dyspnoea on exertion is commonly reported by patients across all levels of airflow limitation,” they write. “The presence of dyspnoea in patients with COPD was associated with markers of greater disease severity and increased risk of poor outcomes.”

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients